Last reviewed · How we verify
Serum tube collection
At a glance
| Generic name | Serum tube collection |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Collagen Fingerprinting for Stratification of PH Patients
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (PHASE2)
- From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis (NA)
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- Validation of Different Methods for HepQuant DuO® Blood Sample Collection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Serum tube collection CI brief — competitive landscape report
- Serum tube collection updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI